A venture capital firm was founded in 2016 and has its main office in Shanghai, China. The firm currently manages three funds including RMB Fund I and Fund II, with a venture USD fund. On average, the initial size of investment is in the $1-6M range, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm has 5 innovation centers across China focusing on different special areas in Life Sciences and medical devices. With over 8 years of operating experience of international medical technology incubators, the firm looks to tailor its services to help portfolio companies reaching key value-added milestones. The firm will consider opportunities based in China and around the globe. The firm actively supports global companies to fast land China market by leveraging the fund’s connections
The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, AI, and Biotechnology R&D Services. The firm is opportunistic in terms of sub-sector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. In terms of therapeutics, The firm will look at products in pre-clinical stages. Regarding medical devices and diagnostics, the firm will invest at any stage of development.
The firm will invest in privately held companies only, and the firm can participate as either lead or co-investor. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply